VEGFR1 (FLT1) Protein

📖 Wiki Page

protein1308 wordssynced 2026-04-02

VEGFR1 (FLT1) Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">VEGFR1 (FLT1) Protein</th>
</tr>
<tr>
<td class="label">Structural Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Full length</td>
<td>1,338 amino acids, ~180 kDa</td>
</tr>
<tr>
<td class="label">Extracellular</td>
<td>7 Ig-like domains (aa 1-764)</td>
</tr>
<tr>
<td class="label">Transmembrane</td>
<td>aa 765-787</td>
</tr>
<tr>
<td class="label">Kinase domain</td>
<td>aa 833-1,058</td>
</tr>
<tr>
<td class="label">Soluble form</td>
<td>sVEGFR1 (~110 kDa, Ig domains 1-6)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P17948</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>FLT1 (chromosome 13q12)</td>
</tr>
</table>

Pathway Diagram

...

VEGFR1 (FLT1) Protein

Pathway Diagram

Mermaid diagram (expand to render)

Vascular Endothelial Growth Factor Receptor 1 (VEGFR1, encoded by the FLT1 gene) is a high-affinity receptor for VEGF family ligands. It plays complex roles in angiogenesis, inflammation, and has been implicated in neurodegenerative disease through its effects on the neurovascular unit, inflammatory responses, and direct neuronal signaling. [@zlokovic2011]

Protein Structure

VEGFR1 (FLT1) is a receptor tyrosine kinase of approximately 180 kDa. It consists of:

Extracellular domain: 7 immunoglobulin-like (Ig-like) domains that constitute the ligand-binding region for VEGFA, VEGFB, and placental growth factor (PlGF). The first three domains are sufficient for high-affinity ligand binding.
Transmembrane domain: A single-pass alpha-helical transmembrane segment anchoring the receptor to the plasma membrane.
Intracellular tyrosine kinase domain: Contains a kinase insert region and the catalytic core that undergoes autophosphorylation upon ligand binding, activating downstream signaling cascades.

VEGFR1 also exists as a soluble form (sVEGFR1/FLT1) generated by alternative splicing of the FLT1 transcript, lacking the transmembrane and kinase domains. Soluble VEGFR1 acts as a natural decoy receptor, sequestering VEGFA and PlGF and preventing their engagement with full-length VEGFR1 or VEGFR2. [@plate1999]

Normal Biological Function

Angiogenesis and Vascular Development

VEGFR1 is a critical regulator of blood vessel formation during development and in adult physiology. It binds VEGFA with ~10-fold higher affinity than VEGFR2 (KDR/FLK1), but has weaker tyrosine kinase activity, making its signaling more nuanced. VEGFR1 acts in two modes:

Decoy function: During development, VEGFR1 sequesters VEGFA, preventing excessive or ectopic angiogenesis by limiting available VEGFA for VEGFR2 signaling. Knockout of FLT1 in mice causes disorganized and excessive vasculature, confirming its regulatory role.

Positive signaling: Under certain conditions (e.g., in inflammatory contexts or with PlGF as ligand), VEGFR1 transduces pro-angiogenic and pro-inflammatory signals via PI3K/Akt, MAPK/ERK, and PLCγ pathways. [@plate1999]

Hematopoietic Regulation

VEGFR1 is expressed on hematopoietic stem cells and vascular endothelial progenitors. The VEGFR1+ hematopoietic stem cell niche is located near blood vessels in the bone marrow. PlGF-VEGFR1 signaling supports hematopoietic stem cell mobilization and recruitment to sites of injury.

Monocyte and Macrophage Migration

A unique feature of VEGFR1 is its expression on monocyte/macrophage lineage cells, where it mediates chemotaxis in response to VEGFA and PlGF. This establishes VEGFR1 as a regulator of inflammatory cell recruitment to sites of angiogenesis and tissue damage.

Role in Neurodegenerative Disease

Alzheimer's Disease

In Alzheimer's disease (AD), VEGFR1 is implicated in neurovascular dysfunction, a recognized component of AD pathogenesis. [@zlokovic2011]

Neurovascular unit dysfunction: The neurovascular unit (NVU), comprising cerebral endothelial cells, pericytes, astrocytes, and neurons, requires coordinated VEGF-VEGFR signaling for maintenance of blood-brain barrier (BBB) integrity and cerebral blood flow. In AD, VEGFR1 expression is dysregulated in brain endothelial cells and pericytes, contributing to:

BBB breakdown: Increased VEGFR1 signaling can increase vascular permeability, contributing to the perivascular leakage observed in AD brains. Leakage of blood proteins (fibrinogen, thrombin) into the brain parenchyma activates microglia and accelerates amyloid pathology. [@ruiz2019]
Amyloid angiopathy: VEGFR1-mediated angiogenesis in AD contributes to the deposition of amyloid-beta (Aβ) in cerebral blood vessel walls (Cerebral Amyloid Angiopathy, CAA). The VEGF-A/VEGFR1 axis promotes abnormal vessel growth that predisposes to CAA.
Impaired Aβ clearance: VEGFR1 signaling affects the expression and function of Aβ transporters (LRP1, RAGE) at the BBB. Dysregulated VEGF signaling impairs the glymphatic and perivascular clearance pathways that normally remove Aβ from the brain.
Cerebral hypoperfusion: AD patients show reduced cerebral blood flow (CBF) and impaired autoregulation. VEGF/VEGFR signaling regulates vasomotor responses; dysregulation contributes to the chronic hypoperfusion that characterizes AD.

Expression studies: Postmortem studies show elevated VEGFR1 protein in AD frontal cortex and hippocampus compared to age-matched controls, particularly in endothelial cells and reactive astrocytes surrounding amyloid plaques. [@ruiz2019]

Parkinson's Disease

VEGFR1 is expressed in dopaminergic neurons of the substantia nigra pars compacta (SNpc), where it may modulate neuroprotection. [@liu2018]

Neurotrophic signaling: In PD models, VEGFA (via VEGFR1) provides trophic support to dopaminergic neurons. In vitro studies show that VEGFA treatment protects SNpc neurons from 6-OHDA and MPTP toxicity, and this protection is mediated through VEGFR1 activation of PI3K/Akt and MAPK pathways.

Microglial activation: VEGFR1 on microglia and infiltrating macrophages mediates their chemotaxis toward VEGF gradients. In the PD SNpc, where chronic neuroinflammation drives progression, VEGFR1-mediated microglial recruitment may amplify the inflammatory cascade. Blocking VEGFR1 signaling reduces microglial activation markers (CD68, Iba1) in mouse models.

Angiogenesis in PD: Unlike AD, where angiogenesis is dysregulated and often counterproductive, PD shows reduced angiogenic signaling. VEGFA and VEGFR1 expression are decreased in PD SNpc compared to controls, and this "angiogenic failure" may contribute to the progressive loss of dopaminergic neurons due to reduced vascular support.

Multiple Sclerosis (for comparison)

Since MS shares neuroinflammatory features with neurodegenerative diseases, VEGFR1 studies in MS are instructive. [@alvarez2011] Active MS lesions show elevated VEGFR1 on endothelial cells and microglia. VEGFR1-mediated angiogenesis is prominent at the borders of chronic active lesions, and anti-VEGF therapy reduces lesion size and inflammatory cell infiltration in EAE models. This suggests VEGFR1 contributes to inflammatory angiogenesis in demyelinating disease.

Stroke and Cerebral Ischemia

Following focal cerebral ischemia, VEGFA and VEGFR1 are rapidly upregulated in endothelial cells, astrocytes, and neurons at the ischemic border. [@kande2015] This represents a compensatory angiogenic response. However, excessive or dysregulated VEGFR1 signaling in the post-ischemic brain can promote vascular leakage, blood-brain barrier disruption, and exacerbate inflammation. Therapeutically, moderate enhancement of VEGF/VEGFR signaling improves post-ischemic recovery, while overactivation worsens outcomes.

Therapeutic Targeting

Anti-Angiogenic Approaches

Given the role of dysregulated angiogenesis and VEGFR1 signaling in AD and cancer, several anti-VEGFR1 strategies have been explored:

Monoclonal antibodies: Anti-VEGFR1 antibodies (e.g., IMC-18F1) block ligand binding and receptor activation. In AD mouse models, anti-VEGFR1 reduces amyloid deposition and improves cognitive performance, but may compromise cerebrovascular integrity.
Tyrosine kinase inhibitors (TKIs): Multi-target anti-angiogenic drugs (sorafenib, sunitinib, pazopanib) inhibit VEGFR1 along with VEGFR2 and other kinases. Their use in AD is limited by BBB penetration and systemic toxicity; local CNS delivery approaches are being explored.
Soluble receptor decoys: AAV-mediated overexpression of sVEGFR1 in the brain reduces VEGFA availability and attenuates pathological angiogenesis in AD models.

Pro-Angiogenic Approaches

For PD, where angiogenic failure may contribute to neuronal loss, pro-angiogenic strategies are being investigated:

VEGFA peptide mimetics: Small peptides that selectively activate VEGFR1, providing neurotrophic support without the edema risk of full-length VEGFA.
PlGF agonists: PlGF (Placental Growth Factor) signals exclusively through VEGFR1 and may provide neuroprotection with better tolerability than VEGFA.
Gene therapy: Viral delivery of VEGFA or PlGF to the SNpc is under investigation in PD models.

Cross-Links

[FLT1 Gene](/genes/flt1) — Gene page for VEGFR1
[VEGF Signaling Pathway](/mechanisms/vegf-signaling-pathway) — VEGF receptor signaling
[VEGF-Angiogenesis Neurodegeneration](/mechanisms/vegf-angiogenesis-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease) — Disease context
[Parkinson's Disease](/diseases/parkinsons-disease) — Disease context
[Neurovascular Unit Dysfunction](/mechanisms/neurovascular-unit-dysfunction) — NVU in neurodegeneration
[Blood-Brain Barrier](/entities/blood-brain-barrier) — BBB and VEGFR1
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms) — VEGFR1 in inflammation
[Cerebral Amyloid Angiopathy](/mechanisms/cerebral-amyloid-angiopathy) — CAA and VEGFR1
[VEGFA Gene](/genes/vegfa) — VEGF-A ligand
[VEGFB Gene](/genes/vegfb) — VEGF-B ligand

External Links

[UniProt: P17948 (FLT1 Human)](/genes/flt1)
NCBI Gene: 2321

References

[Mahley, Apolipoprotein E4: causative agent of pathology (2016)](https://pubmed.ncbi.nlm.nih.gov/27035938/)

[Zlokovic et al., Vascular contributions to Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21150297/)

[Johansson et al., VEGF and VEGFR1 in neurodegenerative disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24954511/)

[Liu et al., VEGFR1 modulates dopamine neuron survival (2018)](https://pubmed.ncbi.nlm.nih.gov/30189277/)

[Plate, Mechanisms of angiogenesis in the brain (1999)](https://pubmed.ncbi.nlm.nih.gov/10029100/)

[Alvarez et al., VEGF and VEGFR1 in multiple sclerosis lesions (2011)](https://pubmed.ncbi.nlm.nih.gov/20331624/)

[Ruiz-Yáñez et al., Angiogenic dysregulation in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31600675/)

[Kande et al., VEGF in cerebral ischemia and neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25904293/)

📖 View canonical wiki page →

VEGFR1 (FLT1) Protein

VEGFR1 (FLT1) Protein

Pathway Diagram

VEGFR1 (FLT1) Protein

Pathway Diagram

Protein Structure

Normal Biological Function

Angiogenesis and Vascular Development

Hematopoietic Regulation

Monocyte and Macrophage Migration

Role in Neurodegenerative Disease

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis (for comparison)

Stroke and Cerebral Ischemia

Therapeutic Targeting

Anti-Angiogenic Approaches

Pro-Angiogenic Approaches

Cross-Links

See Also

External Links

References